
    
      Subjects will have a tumor biopsy before treatment begins. Subjects who are randomized to Arm
      A will receive infusions of STA9090 on days 1, 8, and 15 of a 28 day cycle. Subjects
      randomized on Arm B will receive daily oral dutasteride for 2 weeks prior to beginning
      STA9090 treatment. They will continue to receive dutasteride while on study.
    
  